Navigation Links
Target for potent first-strike influenza drugs identified
Date:8/2/2012

MEMPHIS, Tenn., Aug. 2, 2012 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's Research Hospital have reported details of how certain drugs can precisely target and inhibit an enzyme essential for the influenza virus' replication. Since all strains of the virus require the same functioning enzyme, researchers believe their findings will yield drugs that can effectively treat new strains of the virus, which may be resistant to current antiviral treatments.    

When new strains of influenza emerge, it can take many months for a vaccine to be developed. Experts are concerned that the emergence of any highly virulent strains could result in large numbers of people being hospitalized, and if the strain is or becomes resistant to current treatments, the impact could be catastrophic. The researchers' findings may lead to the ability to develop drugs that not only treat influenza but impede the ability of the virus to develop drug resistance. The study appears online in the August 2 issue of PLoS Pathogens.

St. Jude scientists tested drugs aimed at blocking a dual-purpose enzyme complex, called a polymerase, produced by the influenza virus. This polymerase produces copies of the viral genome during replication. It also assembles molecules called messenger RNA (mRNA) that code for viral proteins the virus needs to hijack the cell's machinery to make it produce more virus.

The drugs that investigators tested target an RNA-snipping enzyme called an endonuclease that is a key subunit of the polymerase complex. The endonuclease enables the virus to disguise its messenger RNA so it will be incorporated into the cell's protein-making machinery. This masking consists of snipping apart cellular mRNA, but retaining a segment called a "cap" that the cell's machinery uses to identify its mRNA. The polymerase then attaches this cap to its own mRNA.

"Inhibitors of the polymerase complex would make excellent drug c
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
2. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
3. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
4. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
5. Whats Next In Vaccines (Malaria, Diabetes, Alzheimers, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
6. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
7. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
8. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
9. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
10. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
11. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
(Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... , NEW YORK , Jan. 26 ... (NYSE Amex: MGT ), and an industry leader in ... which assists radiologists in the early detection of disease, announces ... further request for Additional Information (AI) letter from the US ...
... , CAMBRIDGE, Mass. , ... company, announced today a distribution agreement with OrthoPediatrics Corp., ... sell ETEX,s nanocrystalline calcium phosphate on a non-exclusive basis ... . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ) , ...
Cached Medicine Technology:Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 2Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 3ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp. 2
(Date:12/26/2014)... Aliso Viejo, California (PRWEB) December 26, 2014 ... have announced the TransPack Volume 5 Plugin for Final Cut ... to manipulate a hard light tool to pull off an ... Studios. “When users get their hands on TransPack Volume 5, ... TransPack Volume 5 is a set of over 50 Final ...
(Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
... Ramadoss Friday urged film stars, sportspersons and other celebrities ... interest of public health. ,Addressing the inaugural ... Food Laboratory (CFL) here, he underlined the need for ... the vast population of the country as well as ...
... smoking can be deadly. Hence California and Washington laws imposed strict ... years old physically fit suffered from heart problems that led to ... in smoky taverns for 37 years. So the doctors asked him ... that the indoor air pollution levels in bars that allow smoking ...
... Department of Energy's Brookhaven National Laboratory and colleagues at ... Center in Italy, and Georgetown University it was found ... more effective treatment. This then could be widely used ... were initially tested on rats and the results of ...
... The report of the Mental Health Council of Australia, ... country’s mental health system, the Council //of Australian Governments ... proposed solutions by July. ,However mental health ... lost. The Mental Health Council of Australia launched a ...
... who became orphaned after their HIV-infected parents died four ... Government at a function here tomorrow.// ,The ... take care of the children's health, education and welfare, ... P K Sreemati, who at a recent Cabinet meeting ...
... of overseas doctors after the July 'sittings', thereby providing ... in the UK., ,'Due to low demand, we ... Part 1 exams outside the UK after the sitting ... the government announced., ,Shiv Pande, Chairman of Indo-British ...
Cached Medicine News:Health News:Radiation Therapy Made More Compatible 2Health News:Radiation Therapy Made More Compatible 3Health News:Outcry Against Mental Health Institutions 2Health News:Outcry Against Mental Health Institutions 3
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
For patient-friendly and safe capillary blood collection...
Medicine Products: